Premium
Double‐blind crossover trial of gabapentin in SPG4 ‐linked hereditary spastic paraplegia
Author(s) -
Scheuer K. H.,
Svenstrup K.,
Jennum P.,
á RogviHansen B.,
Werdelin L.,
Fenger K.,
Nielsen J. E.
Publication year - 2007
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2007.01812.x
Subject(s) - gabapentin , medicine , crossover study , hereditary spastic paraplegia , placebo , spastic , double blind , paraplegia , clinical trial , anesthesia , physical therapy , pathology , psychiatry , genetics , spinal cord , gene , phenotype , alternative medicine , cerebral palsy , biology
Patients with hereditary spastic paraplegia (HSP) are often treated with antispastic drugs to relieve symptoms but documentation is lacking. In this study, gabapentin was tested in a double‐blind crossover trial on a group of patients with HSP and linkage to the SPG4 locus. There was no difference between periods with gabapentin and placebo treatment in clinical assessment, self‐reported parameters or paired transcranial magnetic stimulation evaluation of motor cortical excitability.